IQVIA HOLDINGS INC.
IQVIA HOLDINGS INC. (IQV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Notes Offering and Notes Indenture On September 23, 2026, IQVIA Inc. (the “Issuer”), a wholly owned subsidiary of IQVIA Holdings Inc., completed the issuance and sale of $2,000,000,000 in gross proceeds of 6.375% senior notes d
IQVIA Holdings (IQV) priced a $2b senior notes offering due 2034. The company's share price has surged 58.8% in 90 days, with a 1-year return of 42.3%. Analysts estimate a fair value of $275.17, suggesting a modest undervaluation. However, risks include contract pricing pressure and higher leverage. The company's R&D solutions backlog and pipeline growth indicate sustained demand.
IQVIA Holdings priced a $2.0b senior notes offering due 2034 to refinance debt and cover costs. The company launched IQVIA Predictive Clinical Development, an AI-driven platform aimed at accelerating clinical trials. Analysts project revenues of $20.4b and earnings of $2.0b by 2029, but debt remains a key risk. The AI platform could enhance growth and defend pricing power, though competition from in-house pharma tools is a concern.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning IQV (IQVIA HOLDINGS INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent IQV coverage spans corporate actions, financial news and insider activity.
In the last 30 days, IQV insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($1.4M). The most active reporter was Berkshire James G., See Remarks, with 2 filings.
The new debt adds liquidity but increases leverage, likely pressuring the stock short‑term.
The $2 bn issuance increases leverage and may pressure the stock, but provides long‑term funding.
The new senior notes increase leverage but provide cash to retire higher‑cost debt and reduce revolving credit usage.
Fund's positive stance may support short-term buying interest.
Positive analyst consensus may drive short-term buying pressure.
AlphAI scores every news story that mentions IQV with an AI model for sentiment and relevance, and aggregates insider trades from IQVIA HOLDINGS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
IQVIA HOLDINGS INC. (IQV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Notes Offering and Notes Indenture On September 23, 2026, IQVIA Inc. (the “Issuer”), a wholly owned subsidiary of IQVIA Holdings Inc., completed the issuance and sale of $2,000,000,000 in gross proceeds of 6.375% senior notes d
2 min readIQVIA Holdings (IQV) priced a $2b senior notes offering due 2034. The company's share price has surged 58.8% in 90 days, with a 1-year return of 42.3%. Analysts estimate a fair value of $275.17, suggesting a modest undervaluation. However, risks include contract pricing pressure and higher leverage. The company's R&D solutions backlog and pipeline growth indicate sustained demand.
2 min readIQVIA Holdings priced a $2.0b senior notes offering due 2034 to refinance debt and cover costs. The company launched IQVIA Predictive Clinical Development, an AI-driven platform aimed at accelerating clinical trials. Analysts project revenues of $20.4b and earnings of $2.0b by 2029, but debt remains a key risk. The AI platform could enhance growth and defend pricing power, though competition from in-house pharma tools is a concern.
3 min readBroyhill Asset Management's Q2 2026 letter notes IQVIA Holdings (IQV) gained 14% after being a top detractor earlier. The firm trimmed its position, citing strong results and improved business metrics. IQV closed at $265.67, up 10.68% in the past month and 42.21% over the year, with a $43.73B market cap.
2 min readIQVIA Holdings (IQV) has outperformed Agilent Technologies (A) in the diagnostics and research sector, with a 6.4% YTD gain and 14.7% increase over 52 weeks. Analysts give IQV a 'Strong Buy' rating, with a mean price target of $277.16, implying 7.9% upside.
1 min readIQVIA Holdings (IQV) announced an update on its Phase 4 study of pegcetacoplan for rare kidney diseases, tracking real-world effectiveness and safety. The study, recruiting as of September 2026, focuses on outcomes in routine care settings. Positive results could benefit Swedish Orphan Biovitrum and IQV's data services, while issues may impact sector sentiment.
2 min readIQVIA Holdings Inc (NYSE: IQV) plans to issue $2B in senior notes due 2034 to refinance debt, manage credit, and cover fees. GF Value™ rates IQV 4.4% overvalued at $259.21 vs. $248.27. GF Score™ is 92/100, with strong growth and profitability but moderate financial strength. Insiders sold $51.4M in shares over 12 months.
2 min readIQVIA Holdings Inc. (IQV) plans to offer $2 billion in senior notes due 2034. Proceeds will redeem its 2026 notes, repay revolving credit debt, and cover offering expenses. The offering is subject to market conditions and will be offered to qualified buyers.
2 min readBerkshire James G. (See Remarks) sold (to issuer) 2,713 shares of IQVIA HOLDINGS INC. (IQV) at $261.54 ($0.71M total) on 2026-09-02.
1 min readBerkshire James G. (See Remarks) sold 2,668 shares of IQVIA HOLDINGS INC. (IQV) at $261.33 ($0.70M total) on 2026-09-02.
1 min read
